Rafael Holdings subsidiary Cyclo Therapeutics licenses MIT patent for cyclodextrins in ApoE4+ Alzheimer's

Rafael Holdings, Inc.

Exclusive license covers U.S. Patent No. 12285440 for cyclodextrins in ApoE4-positive Alzheimer's patients.
ApoE4 variant present in 50-70% of Alzheimer's patients; Trappsol Cyclo targets cholesterol transport in CNS.
Phase 3 results for Transport NPC program due in calendar Q3 2026, per COO Joshua Fine.
CEO Howard Jonas calls the license a transformative milestone for the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.